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IMPORTANCE Delirium is associated with accelerated cognitive decline. The pathologic
substrates of this association are not yet known, that is, whether they are the same as those
associated with dementia, are independent, or are interrelated.
OBJECTIVE To examine whether the accelerated cognitive decline observed after delirium is
independent of the pathologic processes of classic dementia.
DESIGN, SETTING, AND PARTICIPANTS Harmonized data from987 individual brain donors from
3 observational cohort studies with population-based sampling (Vantaa 85+, Cambridge City
Over-75s Cohort, Cognitive Function and Ageing Study) performed from January 1, 1985,
through December 31, 2011, with a median follow-up of 5.2 years until death, were used in
this study. Neuropathologic assessments were performedwith investigators masked to
clinical data. Data analysis was performed from January 1, 2012, through December 31, 2013.
Clinical characteristics of brain donors were not different from the rest of the cohort.
Outcome ascertainment was complete given that the participants were brain donors.
EXPOSURES Delirium (never vs ever) and pathologic burden of neurofibrillary tangles,
amyloid plaques, vascular lesions, and Lewy bodies. Effects modeled using random-effects
linear regression and interactions between delirium and pathologic burden were assessed.
OUTCOMES Change in Mini-Mental State Examination (MMSE) scores during the 6 years
before death.
RESULTS There were 987 participants (290 from Vantaa 85+, 241 from the Cambridge City
Over-75s Cohort, and 456 from the Cognitive Function and Ageing Study) with
neuropathologic data; mean (SD) age at death was 90 (6.4) years, including 682 women
(69%). ThemeanMMSE score 6 years before death was 24.7 points. The 279 individuals with
delirium (75%women) had worse initial scores (−2.8 points; 95% CI, −4.5 to −1.0; P < .001).
Cognitive decline attributable to deliriumwas −0.37 MMSE points per year (95% CI, −0.60 to
−0.13; P < .001). Decline attributable to the pathologic processes of dementia was −0.39
MMSE points per year (95% CI, −0.57 to −0.22; P < .001). However, the combination of
delirium and the pathologic processes of dementia resulted in the greatest decline, in which
the interaction contributed an additional −0.16MMSE points per year (95% CI, −0.29 to
−0.03; P = .01). Themultiplicative nature of these variables resulted in individuals with
delirium and the pathologic processes of dementia declining 0.72MMSE points per year
faster than age-, sex-, and educational level–matched controls.
CONCLUSIONS AND RELEVANCE Delirium in the presence of the pathologic processes of
dementia is associated with accelerated cognitive decline beyond that expected for delirium
or the pathologic process itself. These findings suggest that additional unmeasured
pathologic processes specifically relate to delirium. Age-related cognitive decline has many
contributors, and these findings at the population level support a role for delirium acting
independently andmultiplicatively to the pathologic processes of classic dementia.
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U nderstanding the pathologic basis of cognitiveimpairment in whole populations is a prerequisite tomitigating the increasing public health burden of
dementia.1 Many strands of investigation presuppose that
Alzheimer, vascular, and Lewy body pathologic features are
the predominant causes of dementia. This paradigm has
directed the search for biomarkers, treatments, and potential
prevention strategies. However, evidence indicates that
these classic pathologic processes do not fully account for
the clinical syndrome,2 especially in unselected populations
of the oldest-old.3,4 For example, older people may have a
large burden of the pathologic processes of classic dementia
but no associated clinical dementia and vice versa.
Delirium is a syndrome of acute brain dysfunction char-
acterized by inattention and other mental status impair-
ments. It is a major public health problem that affects at
least 20% of older inpatients and has well-documented
adverse associations.5 An emerging literature reveals that
delirium is a strong predictor of new-onset dementia and
acceleration of existing cognitive decline.6-10 These results
are consistent across several different settings: after
hospitalization,11 in those with dementia,6,12 in postopera-
tive patients,13 and in a community population.8 In multiple
animal models of neurodegeneration, triggers of acute cog-
nitive dysfunction, such as systemic inflammation, also
exacerbate the pathologic processes14,15 and accelerate func-
tional decline during longer periods.16,17 This finding implies
that delirium and/or its causes can contribute to the overall
burden of dementia. Moreover, research indicates that 3 of
10 cases are preventable,18 which in turn suggests that
delirium interventions might reduce at least some cognitive
decline and dementia.
Although delirium is now established as a strong predic-
tor of cognitive decline in older adults,6,8,12 whether it ac-
counts for additional, interrelated, or unexplained patho-
logic injury that contributes to dementia has not previously
been examined. It is possible thatwhen dementia follows de-
lirium it has a different pathologic profile compared with de-
mentia that develops without delirium. Therefore, under-
standinghowdeliriumaffects theevolutionofdementia in the
context of a particular burden of pathologic findings may of-
fer new insights into independent mechanisms that explain
cognitive decline after delirium.
In this study, the challengewas to examine a key hypoth-
esis: that faster cognitive decline associated with delirium
would act independently of the cognitive decline associated
with the pathologic processes of classic dementia. Accord-
ingly, we investigated the extent to which delirium and the
pathologic processes of classic dementia contributed to asso-
ciated cognitivedecline in 3unselected, population-based co-
hort studies with neuropathologic autopsy data: the Medical
ResearchCouncilCognitiveFunctionandAgeingStudy (CFAS),
the Cambridge City Over-75s Cohort (CC75C), and the Vantaa
85+ study. These studies represent the entirety of such stud-
ies conducted in Europe and provide a unique opportunity to
increase the understanding of the clinical significance of de-
liriumand its interrelationwith thepathologicprocessesofde-
mentia in the general population.
Methods
The individual studies have previously been described in
detail,19-21 andparticipant-level datahavebeenharmonizedas
the Epidemiological Clinicopathological Studies in Europe
(EClipSE) collaboration.22 Briefly, participants were sampled
from general practitioners’ registers (CFAS [1991-2011] and
CC75C [1985-2011] in the United Kingdom) and the Popula-
tion Register Centre (Vantaa 85+ in Finland [1991-2001]) from
January 1, 1985, throughDecember 31, 2011. Data analysiswas
performed from January 1, 2012, through December 31, 2013.
The CFAS recruited persons 65 years or older, the CC75C re-
cruitedpersons75yearsorolder, andVantaa85+ recruitedper-
sons 85 years or older. Individuals were assessed mostly at
2- to 4-year intervals, with some subsamples having annual
evaluation.TheMini-Mental StateExamination (MMSE)23was
performed in all 3 studies. Additional neuropsychological bat-
teries were also performed, with some differences among the
studies (eAppendix in theSupplement).Table 1summarizes the
characteristics of each cohort. Previous work found that par-
ticipants in the brain donor programs had no systematic dif-
ferences in clinical characteristics compared with other par-
ticipants in the cohorts,24 although donors in the CFAS were
selectedbystratified randomsampling,weighted to thosewho
wereolderandcognitively impaired.Eachstudyhad local ethi-
cal approval (CFAS centers: Cambridge: North West Anglia
HealthAuthority Local ResearchEthics Committee [Peterbor-
ough]; Huntingdon Local Research Ethics Committee; Cam-
bridgeLocalResearchEthicsCommittee;Gwynedd:Gwynedd
Hospitals National Health Service Trust–North West Health
Authority Research Ethics Committee (West); Liverpool:
Liverpool Local ResearchEthics Committee;Newcastle: New-
castle & North Tyneside Health Authority–Joint Ethics Com-
mittee; Northumberland and Tyne &Wear Health Authority–
Local Research Ethics Committee; Nottingham: Queen’s
Medical Centre National Health Service Trust Ethics Commit-
tee; Nottingham University Medical School Ethical Commit-
tee;CityHospitalEthicsCommittee;Oxford:OxfordshireHealth
Authority: CentralOxfordResearchEthicsCommittee; CC75C:
Cambridge Research Ethics Committee; and Vantaa 85+:
EthicsCommitteeof theCityofVantaa).Written informedcon-
sent was provided for each study, and all analyses were con-
ducted with deidentified data.
Key Points
Question What is the association among delirium, the pathologic
processes of dementia, and cognitive decline in older persons?
Findings In this cohort of 987 autopsied brains from3population-
based cohort studies, deliriumand thepathologic processes of
dementiawere associatedwith cognitive decline; however, the
combination of deliriumand thepathologic processes of dementia
interacted to give the fastest trajectory of cognitive decline.
Meaning During cognitive decline in the oldest-old, delirium
appears to act independently andmultiplicatively to the
neuropathologic processes of classic dementia.
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DeliriumAssessments
In the CFAS and CC75C, delirium symptomswere a feature of
the standardized interviewschedules administeredby trained
interviewers to participants and informants. These sched-
ules assigned diagnostic groups based on validated, struc-
tured algorithms for psychiatric disorders, themselves based
on DSM-III-R or related classifications.25 Questions included
the following: “Were there brief episodes during the 24hours
when s/he seemed much worse and then times when quite
clear?” “Were theremarked fluctuations in his/her level of at-
tention or alertness?” “Could a physical illness…be sufficient
explanation for the subject'smental or psychiatric symptoms
(eg, delirious due to acute infection)?” A full list of relevant
questions is given in the eAppendix in the Supplement.
At each interview in the Vantaa 85+ study, the examining
neurologists assessed participants and informant(s) for a his-
tory of any episodes of delirium,with reference to a checklist
ofDSM-III-Rcriteria fordeliriumdiagnosis.26The reportedhis-
tory was corroborated with medical case records that were
available at the time of assessment such that the study ascer-
tainment of delirium was retrospectively derived from mul-
tiple sources and the overall diagnosis accepted if the exam-
ining neurologists judged there was sufficient evidence from
participant and informant recall and/or indication in themedi-
cal records.
Neuropathologic Analyses
Paraffin-embedded brain tissue samples were used to assess
neuropathologic markers with investigators masked to clini-
cal data. Each study reported Braak stage as a semiquantita-
tivemeasure of τ neurofibrillary tangles andneocortical amy-
loidplaqueburden fromtheConsortiumtoEstablishaRegistry
for Alzheimer’s Disease protocol.27 The presence of infarcts
(>10 mm), lacunes, and hemorrhage was histologically as-
sessedusing hematoxylin-eosin. Lewybodies in the substan-
tia nigra were assessed with hematoxylin-eosin but also in-
cluded immunohistochemical staining against α-synuclein
(or ubiquitin in some of the earlier CC75C specimens)
(eAppendix in the Supplement).
Statistical Analysis
Consistentwith previous approaches, deliriumexposurewas
operationalized as never or ever.8 Change in MMSE score be-
fore death was modeled using a time-to-death random-
effects (random slopes) model.28 We were interested in esti-
mating the final trajectory towarddeathbecause this approach
makes associationswith pathologic data easier to define. The
mean time from the start of the trajectory identified by the
model to deathwas 5.2 years; therefore, the start point (inter-
cept) for this trajectorywas set (centered) at 6 years. This start
point is not so near the point of death that rates of change
(slopes) cannot be estimatedyet not so far fromdeath that the
pathologic findings at autopsymight not plausibly be related
to theestimatedparameters. Sixyearsbeforedeath isalsocom-
parable to start points from change-point models of the final
trajectory of cognitive decline29-31 and in the range observed
inother analyses (3-8 years).32Modelswere adjusted for base-
line MMSE score, age at death (centered at a mean age of 90
years), sex (0 for men, 1 for women), years of education (0-3,
4-7, 8-11, or ≥12), and study. Missing data were assumed to be
missing at random given that outcome ascertainment was
essentially complete in this brain donor cohort.
The 4 neuropathologic variables of classic dementia
that contribute the greatest population-attributable risk for
dementia4wereexamined:Braakstage(neurofibrillary tangles),
neocorticalamyloidplaques,vascularpathologic findings (large
artery infarcts, lacunes,orhemorrhage),andLewybodies in the
substantia nigra. In keeping with previous methods, neuro-
pathologicvariablesweredichotomized(0,nonetomild;1,mod-
erate to severe).3,8,24This approachallows for simpler interpre-
tationand ismore likely tobe robust. Individualswereassigned
a pathologic burden score based on the number of times they
scored in the higher category for each of the 4markers. There-
fore, theoverall pathologicburdenscore ranged from0to4 (ie,
being in the lower category for all markers [pathologic burden
score of 0], in the upper category of all 4 markers [pathologic
burden score of 4], or some combination). Finally, interac-
tions between delirium and pathologic burden ([delirium his-
tory] × [pathologic score]) in terms of their effect on both the
start point (−6 years before death) and rate of change ofMMSE
scoreswere calculated. Full details are given in the eAppendix
intheSupplement.AllanalyseswereconductedwithSTATAsta-
tistical software, version 12.1 (StataCorp). P valueswere calcu-
lated though tests of maximum likelihood, where P < .05 was
considered significant. All tests were 2-tailed.
Results
Therewere987participants (290fromVantaa85+,241 fromthe
CC75C, and 456 from the CFAS) with neuropathologic data
(mean[SD]ageatdeath,90[6.4]years;472 females [67%]with-
outdeliriumand210[75%]withdelirium).Table2describes the
characteristicsofthesample.Personswithdeliriumwereslightly
Table 1. Characteristics of Studies Comprising the EClipSE Database
Source
Total No.
of Patients Site Age, y
Baseline
Survey Year Follow-up, y
No. of
Surveysa
Donors,
No. (%)
Vantaa 85+ 553 Vantaa, Finland ≥85 1991 10 5 290 (52.4)
CC75C 2166 Cambridge, England ≥75 1985 25 9 241 (11.1)
CFAS 18 226 UK multicenterb ≥65 1993 10 7 456 (2.5)
Abbreviations: CC75C, Cambridge City Over-75s Cohort; CFAS, Cognitive Function and Ageing Study; EClipSE, Epidemiological Clinicopathological Studies in Europe.
a Number of surveys refers to themaximum number of times a participant could have been seen up to themost recent follow-up point.
b The CFAS sampled from 6 geographic areas: 4 urban (Newcastle, Nottingham, Liverpool, and Oxford) and 2 rural (Cambridgeshire, Gwynedd).
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older, more likely to be women, andmore likely to havemore
yearsofeducation.Neocorticalamyloidplaques,vascularpatho-
logic findings, or Lewy bodies were not significantly different
in individuals with andwithout a history of delirium.
Results fromthe random-effectsmodels thatdescribedde-
lirium and cognitive decline are presented in Table 3. Theme-
diannumberof longitudinalobservations forparticipants in the
modelwas2(interquartilerange,1-4). Inthefullyadjustedmodel
(includingdeliriumandpathologicburden), the startpointwas
estimated at 24.7 MMSE points. The start point should be in-
terpreted as the estimatedMMSE score 6 years before death in
persons inwhomall covariatesare in thereferencecategory (eg,
youngestage,nodelirium).Forthetypical90-year-old, themean
base rate of decline was 0.35 points per year (base rate indi-
cates all covariates in the reference category, eg, no delirium,
lowest pathologic score). Therewasno significant influence of
study source (Vantaa 85+, CC75C, or CFAS) on the model esti-
mates (eAppendix in the Supplement).
Effect of Delirium on Start Point and Rate of Change
Delirium was associated with a mean 2.8-point lower MMSE
score (P < .001) 6 years before death. For these persons, the
rateof changewasanadditional0.37pointsperyear (P < .001).
These coefficients are additive. Therefore, for the typical in-
dividual aged 90 years at death with delirium, the estimated
MMSE score is 24.7 points (baseline) with −2.8 points equal-
ing 21.9MMSEpoints, declining at0.35points (base rate)with
−0.37 (attributable to delirium) equaling0.72 points per year.
Effect of Pathologic Burden on Start Point
and Rate of Change
An increasing pathologic burden score was associated with a
lowerMMSEscore (−0.7 for 1 instanceofhighdementiapatho-
logic marker, −2.2 point for 2markers, and −4.4 for 3 ormore
markers; P < .001). Pathologic burden conferred an addi-
tional 0.39-point decline in MMSE score over and above the
effects of age and delirium (P < .001).
Interaction Between Delirium and Pathologic Burden
Asignificant interactionbetweendeliriumandpathologicbur-
den estimated an additional decline of 0.16MMSE points per
year (P = .01). Therefore, individuals with delirium and high
dementia pathologic burdenhad estimated rates of decline of
−0.35 points (base rate), −0.37 points (attributable to de-
Table 2. Characteristics of Study Participants According to History of Deliriuma
Characteristic
No Delirium
(n = 708)b
Delirium
(n = 279)b P Valuec
Follow-up, median (IQR), y 4.3 (2.0-7.1) 4.7 (2.5-7.8) NA
No. of assessments in last 6 y, median (IQR)d 2 (1-3) 3 (2-4) NA
Study
Vantaa 85+ (n = 290) 232 (80.0) 58 (20.0)
NACC75C (n = 241) 142 (58.9) 99 (41.1)
CFAS (n = 456) 334 (73.2) 122 (26.8)
Age at death, mean (SD), y 89 (6.7) 90 (5.8) .03
Female 472 (66.7) 210 (75.3) <.001
Years of education, median (IQR) 9 (6-13) 9 (8-14) <.001
Pathologic findinge
Braak stage (n = 978) 346 (50.6) 166 (56.5) .09
Neocortical amyloid plaques (n = 960) 344 (49.7) 138 (51.5) .62
Vascular (infarcts, lacunes, or hemorrhages) (n = 884) 358 (55.6) 139 (57.9) .54
Lewy bodies in substantia nigra (n = 967) 67 (9.7) 27 (9.7) .99
Pathologic burden scoref
0 132 (18.6) 40 (14.3)
.10
1 207 (29.2) 72 (25.8)
2 220 (31.1) 107 (38.4)
3 or 4 149 (21.0) 60 (21.5)
Any moderate to severe pathologic burdeng 576 (81.4) 239 (85.7) .20
Abbreviations: CC75C, Cambridge City Over-75s Cohort; CFAS Cognitive
Function and Ageing Study; IQR, interquartile range; NA, not applicable.
a Data are presented as number (percentage) of patients unless otherwise
indicated.
bDeliriummeans evidence of delirium at any time compared with those with no
history of delirium.
c P values for differences in means andmedians (continuous measures) were
obtained by 2-sample t test or Wilcoxon test, and proportions were tested
using χ2 tests.
d Six years is the chosen intercept for this model describing the final trajectory
of cognitive decline.
e Pathologic measures are dichotomized. Numbers given here are for the higher
category (Braak stage ranges from0 to 6); figures are those scoring 4, 5, or 6.
Neocortical amyloid plaques scored as none, mild, moderate, or severe;
figures are those scoring moderate to severe. Vascular indicates the presence
(yes/no) of infarcts in arteries larger than 10mm, lacunar lesions, or
hemorrhage. Lewy bodies scored as none, mild, moderate, or severe; figures
are those scoring moderate to severe. Full details are given in the eAppendix in
the Supplement.
f Pathologic burden score refers to the number of pathologic measures in a
higher category for an individual.
g Anymoderate to severe pathologic findings were scored as a pathologic
burden score of 1 or higher.
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lirium), −0.39 points (attributable to pathologic burden), and
−0.16 points (attributable to interaction), which equals 1.27
points per year. In comparison, the independent effect of age
alone on the rate of MMSE score change was 0.01 points per
year (ie, MMSE score difference of 0.05 between the ages of
85 and 90 years).
The Figure shows how the rate of cognitive decline varies
bydeliriumandpathologicstatus.Theslowestdeclinewasseen
inpersonswithnohistoryofdeliriumandleastdementiapatho-
logicburden.The fastestdeclinewasseen inpersonswithahis-
tory of delirium andmost dementia pathologic burden. Inter-
mediate rates of decline were observed in individuals with
deliriumbut leastdementiapathologicburdenandinthosewith
no delirium history butmost dementia pathologic burden.
Discussion
This is the first report, to our knowledge, that peoplewith de-
lirium and higher levels of pathologic processes of classic de-
mentia have the greatest cognitive decline. Delirium in the
presence of dementia-relatedneuropathologic processeswas
associatedwith cognitivedeclinebeyond that expected forde-
liriumor theneuropathologicprocess itself.This findingmeans
that delirium may be independently associated with patho-
logic processes that drive cognitive decline, which are differ-
ent from the pathologic processes of classic dementia. These
findings suggestnewpossibilities regarding thepathologic cor-
relates of cognitive impairment, positioning delirium, and/or
its precipitants as a critically interrelated mechanism.
These results are in keepingwith other studies identified
in a systematic review33 reporting that delirium is associated
with faster trajectories of cognitive decline.6,8,13 A previous
report8 from the Vantaa 85+ study raised the possibility that
the pathologic processes of classic dementiamight notmedi-
ate the observed association between delirium and demen-
tia, although theanalysiswasunderpowered. In this study, the
larger sample size and themoreprecise determinationof cog-
nitive change in the 6 years before death allow us to be more
conclusive about the interrelated effect of delirium on clini-
copathologic correlations indementia.Experimentaldata from
mousemodels suggest that deliriummayarise through the in-
Table 3. Quantifying Trajectories ofMini-Mental State Examination Change in Relation to Delirium and Dementia Pathologic Burdena
Variable
Clinical
(n = 877 Cases
and 2570 Observations)
Clinical and Delirium
(n = 877 Cases
and 2570 Observations)
Clinical and
Pathologic Burden
(n = 872 Cases
and 2558 Observations)
Clinical, Delirium,
and Pathologic Burden
(n = 872 Cases
and 2558 Observations)
β (95% CI) P Value β (95% CI) P Value β (95% CI) P Value β (95% CI) P Value
Intercept 21.73 (19.98 to 23.48) <.001 22.18 (20.51 to 23.85) <.001 24.76 (22.84 to 26.67) <.001 24.65 (22.77 to 26.53) <.001
Slope −0.86 (−0.93 to −0.78) <.001 −0.66 (−0.74 to −0.58) <.001 −0.45 (−0.60 to −0.31) <.001 −0.35 (−0.51 to −0.20) <.001
Age −0.27 (−0.33 to −0.20) <.001 −0.25 (−0.31 to −0.19) <.001 −0.23 (−0.29 to −0.16) <.001 −0.21 (−0.27 to −0.15) <.001
Age × slope −0.02 (−0.03 to −0.01) <.001 −0.02 (−0.03 to −0.00) <.001 −0.01 (−0.02 to −0.00) <.001 −0.01 (−0.02 to −0.00) .05
Sex −2.08 (−2.81 to −1.34) <.001 −1.96 (−2.69 to −1.24) <.001 −2.08 (−2.80 to −1.35) <.001 −1.98 (−2.70 to −1.27) <.001
Educational
level, y
0-3 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
4-7 0.99 (−0.94 to 2.78) .33 1.17 (−0.66 to 2.88) .22 0.88 (−0.91 to 2.66) .34 1.06 (−0.66 to 2.77) .23
8-11 1.93 (−0.91 to 4.77) .12 1.22 (−1.51 to 3.95) .24 1.49 (−1.24 to 4.22) .20 0.73 (−1.90 to 3.37) .57
≥12 5.55 (2.68 to 8.43) <.001 4.56 (1.79 to 7.33) <.001 5.18 (2.41 to 7.94) <.001 4.16 (1.49 to 6.83) <.001
Delirium −3.84 (−4.62 to −3.06) <.001 −2.75 (−4.49 to −1.01) <.001
Delirium × slope −0.62 (−0.77 to −0.48) <.001 −0.37 (−0.60 to −0.13) <.001
Pathologic
burden score
0 1 [Reference] .04 1 [Reference] .24
1 −1.30 (−2.33 to −0.26) <.01 −0.67 (−1.79 to 0.45) <.001
2 −2.83 (−3.86 to −1.79) <.01 −2.22 (−3.34 to −1.09) <.001
3 or 4 −4.81 (−6.04 to −3.58) <.01 −4.40 (−5.71 to −3.10) <.001
Pathologic
burden × slope
−0.51 (−0.68 to −0.35) −0.39 (−0.57 to −0.22) <.001
Delirium ×
pathologic burden
interaction (intercept)
−0.86 (−2.75 to 1.03) .37
Delirium ×
pathologic burden
interaction (slope)
−0.16 (−0.29 to −0.03) .01
a The term dementia pathologic burden refers to classic dementia pathologic
variables known to contribute to cognitive impairment (ie, Braak stage,
amyloid plaques, infarcts, and Lewy bodies).Observations refers to the total
number of longitudinal outcomes in themodel. Each of the 4 columns
represents a model of cognitive trajectories adjusted by study source. The
intercept and slope are given for eachmodel. These variables indicate the
estimatedMini-Mental State Examination scores 6 years before death
(intercept) and the rate of decline per year (slope). The intercept from 6 years
before death was chosen because themean time before death was 5.2 years,
and themodel is centered just before themean. The figures given in this row
are for the baseline group, that is, where all other variables in themodel are in
the lowest category.
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teractionbetween systemic or central nervous system inflam-
mationandexistingneurodegenerativepathologicprocesses,34
and acute exacerbation of inflammation clearly leads to neu-
ronal death,14 synaptic changes,35 and accelerated decline.36
These changes occur independently of increased extracellu-
lar amyloid. However, we now need to know whether indi-
vidualswithdeliriumsuperimposedondementia havediffer-
ent patterns of inflammation, synaptic loss, axonal pathologic
findings, and/or differential loss of key neuronal populations
of the hippocampus and cortex and of cholinergic and norad-
renergic projection areas.37
Strengths and Limitations
This analysis has a number of strengths. It focuses on amajor
question arising from the prevalence of cognitive impair-
ment and aging. In terms of study design, the 3 cohorts have
high generalizability for the oldest-old populations, who are
underrepresented in dementia research despite having the
highest prevalence of dementia.38 This is also the first article,
toourknowledge, toexaminedeliriumand thepathologic cor-
relatesofcognitivedeclineat theendof life in thegeneralpopu-
lation; the other analysis comes from a leading study in this
area, the Religious Orders cohort study,30 which is, however,
focused on specific populations. Modeling change in cogni-
tive outcomes as continua rather than simply the presence or
absence of dementia allows for an exploration of the effect of
delirium across thewhole spectrumof cognitive function (ie,
from no baseline impairment throughmild cognitive impair-
ment tomore severe dementia severity). The power to assess
sucheffects as interactionsbetweendeliriumandneuropatho-
logic processes is unique.
A number of limitations should be taken into account.
Delirium was retrospectively ascertained and by slightly dif-
ferentmethods. In theVantaa 85+ study, assessments for his-
toryofdeliriumoccurredat eachvisit, using information from
participants, informants, and medical records. Ascertain-
ment of data in the CFAS and CC75C relied on diagnostic in-
terviews at each study visit, but these data are likely to un-
derestimatedelirium in the interveningperiod.Thediagnostic
classification criteria also varied, although the different diag-
nostic schedules for delirium have good agreement with
DSM-III-R.39 Despite these differences, the results appear to
be consistent across the cohorts. The implication, eitherway,
is that core symptoms in delirium—acute fluctuating change
in attention in associationwith acute illness—represent an ad-
verse state for subsequent cognitive trajectories regardless of
the exactmethods for operationalizing the syndrome.Aswith
other prospective cohort data, the possibility remains that re-
sidual confounding contributes to these observed associa-
tions. Another consideration is that only a limited range of
pathologic markers and comorbidities could be examined in
this harmonized data set. Finally, although recent research
basedonneuroimagingandneuropathologicexaminationsug-
gests that insults in earlier life can also bemalignant,40-42 this
hypothesis could not be examined within this study.
Conclusions
Our results indicate that delirium interacts with underlying
pathologic processes of classic dementia and so represents a
potential independent but interrelatedpathologic pathway to
chronic cognitive impairment and dementia. If delirium pre-
ventioncould lead to consequentpreventionofdementia,43,44
it will be essential to understandwhether certain dimensions
of the delirium syndromemight have a greater effect on cog-
Figure. Trajectory of Cognitive Decline in Relation to Delirium and Dementia Pathologic Burden at Autopsy
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P < .001 for line C vs D, and P = .01 for line A vs C. MMSE indicates Mini-Mental
State Examination.
Research Original Investigation Association of DeliriumWith Cognitive Decline in Late Life
E6 JAMAPsychiatry Published online January 18, 2017 (Reprinted) jamapsychiatry.com
Downloaded From: http://jamanetwork.com/pdfaccess.ashx?url=/data/journals/psych/0/ by a University College London User  on 02/15/2017
Copyright 2017 American Medical Association. All rights reserved.
nitive trajectories than others. For example, duration, sever-
ity, and/or cause (eg, medications vs acute illness, surgery vs
sepsis) may be differently important. The degree of preexist-
ing multimorbidity or frailty may have a significant bearing.
Animal studiesmodeling different causes and severities have
some scope to elucidate some of these questions, but greater
clarity on these issues must also come from careful prospec-
tive studies in representative populations. Nonetheless, our
findings indicate that clinicians need to be alert to older
people’s cognitive changes during acute episodes and in
follow-up across all settings and therefore support wider
implementation of best practice in delirium prevention.45
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